Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2226

1.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

2.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.

Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9.

PMID:
22411424
3.

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.

Bonafede M, Joseph GJ, Princic N, Harrison DJ.

J Med Econ. 2013 Sep;16(9):1120-8. doi: 10.3111/13696998.2013.820192. Epub 2013 Jul 18.

PMID:
23808901
4.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
5.

Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.

Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ.

J Manag Care Spec Pharm. 2014 Dec;20(12):1236-44.

6.

Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.

Wu N, Lee YC, Shah N, Harrison DJ.

Clin Ther. 2014 Aug 1;36(8):1231-41, 1241.e1-3. doi: 10.1016/j.clinthera.2014.06.014. Epub 2014 Jul 23.

PMID:
25062652
7.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
8.

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.

J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8.

PMID:
22115327
9.

Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.

Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR.

Adv Ther. 2014 Apr;31(4):410-25. doi: 10.1007/s12325-014-0110-3. Epub 2014 Mar 7.

PMID:
24604700
10.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
12.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
13.

The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.

Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, Escudero-Vilaplana V, Fernández-Fuente MA, Ferrit-Martin M, Gómez-Germá P, Martínez-Sesmero JM, Mayorga-Pérez J, Menchén-Viso B, Merino-Alonso J, Polache-Vengud J, Sánchez-Guerrero A.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):851-8. doi: 10.1586/14737167.2015.1044514. Epub 2015 May 14.

PMID:
25972066
15.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

16.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

17.

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.

Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW.

J Med Econ. 2014 Jan;17(1):1-10. doi: 10.3111/13696998.2013.856314. Epub 2013 Oct 31.

PMID:
24131136
18.

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.

Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW.

J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774. Epub 2015 Sep 30.

PMID:
26337538
19.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

20.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

Supplemental Content

Support Center